Group 1 - CICC is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, with trading resuming on December 18, 2025 [1] - Victory Energy's major shareholder plans to transfer 29.99% of its shares to Qiteng Robotics, with no plans for asset restructuring in the next 12 months [2] - China Metallurgical Group intends to repurchase A-shares worth 1 to 2 billion yuan at a price not exceeding 4.9 yuan per share [3] Group 2 - Boten Co. plans to acquire part of the Yifeng Yunding Fund for 1 yuan, with a commitment to fulfill a 20 million yuan capital contribution [4] - Tongyou Technology has initiated a 50 million yuan accounts receivable factoring business [5] - Gaode Infrared has received approval to issue debt financing tools totaling up to 3 billion yuan [6] Group 3 - Zhengyu Industrial's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] - China CRRC signed contracts totaling approximately 53.31 billion yuan, accounting for 21.6% of its projected 2024 revenue [9] - High Energy Environment's director increased his stake by purchasing 56,100 shares [10] Group 4 - Shantou Technology received approval from the CSRC for a convertible bond issuance [11] - Puyang Co. plans to use up to 900 million yuan of idle funds for entrusted wealth management [12] - Huibai New Materials has been awarded a government subsidy of 3.8 million yuan, with the first installment of 2.12 million yuan already received [13] Group 5 - Jiayuan Technology's shareholders plan to transfer 2.51% of the company's shares through a pricing inquiry [14] - Lingpai Technology's subsidiary terminated a 125 million yuan procurement contract due to market changes [15] - Juguang Technology intends to use up to 200 million yuan of idle funds for cash management [16] Group 6 - Zhongwen Media's subsidiary terminated a 200 million yuan private equity fund subscription due to market changes [17] - Zhifei Biological's modified vaccine for monkeypox has received clinical trial acceptance [19] - GeKowei's subsidiary received a government subsidy of 60 million yuan, accounting for 32.12% of the company's audited net profit [20] Group 7 - Wantai Biological's application for a clinical trial of a respiratory syncytial virus vaccine has been accepted [21] - Haitai Technology plans to increase capital in its Thai joint venture from 500,000 to 3 million Thai baht [22] - Shanghai Airport signed contracts for the transfer of duty-free store operating rights [23] Group 8 - Del Shares received approval to issue shares for the acquisition of 100% of Aizhuo Intelligent [24] - Novozymes' products have obtained EU CE IVDR certification [25] - Shibai Testing's chairman's assistant plans to increase shareholding by 8 to 12 million yuan [26] Group 9 - Huitian New Materials plans to invest approximately 97.68 million yuan in a lithium battery anode glue project [27] - Pudong Construction's subsidiaries won contracts totaling 1.649 billion yuan [29] - Acolyte's subsidiary has entered trial production for a special high-temperature resistant resin project [30] Group 10 - Pingzhi Information's subsidiary signed a 38.25 million yuan computing power service contract [31] - Tianma Technology is required to pay 5.3625 million yuan in taxes and penalties [32] - Yahon Pharmaceutical's clinical trial application for GLX002 has been approved [34]

一、获证产品的基本情况 证券代码：688105 证券简称：诺唯赞 公告编号：2025-056 南京诺唯赞生物科技股份有限公司 关于自愿披露公司产品取得欧盟CE IVDR认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）六项呼吸道病原体 核酸检测试剂盒于近日取得欧盟 CE IVDR 认证，可在欧盟国家和认可欧盟 CE 认 证的国家进行销售，具体情况如下： （一）认证信息 | 名称 | 分类 | 有效期至 | | 证书编号 | 预期用途 | 参考图示 | | --- | --- | --- | --- | --- | --- | --- | | Logilet Respiratory | | 2030 | 年 | EU-QMS-FI 01219-8000 | 用于辅助诊断呼吸道 合胞病毒、甲型流感病 | | | Pathogen Panel | Class | 12 月 | 9 日 | 33-2025 | 毒、乙型流感病毒、严 | | | 六项呼吸道病 | B | 2 ...

公司本次获欧盟 CE IVDR 准入资质的六项呼吸道病原体核酸检测试剂盒，搭配公司数字微流控 Logilet Logicore 检测系统，依托微流控芯片完成待测样本的核酸提取、扩增、检测全流程操作，可精准检测呼 吸道合胞病毒、甲型流感病毒、乙型流感病毒、严重急性呼吸综合征冠状病毒 2 型、腺病毒及肺炎支原 体共6 项呼吸道病原体，能够真正实现"样本进，结果出"的全自动化基因检测，为临床检测、疾控检疫 和科学研究等应用场景提供更为安全高效、小巧便携、快速精准的解决方案。 格隆汇12月17日丨诺唯赞(688105.SH)公布,公司六项呼吸道病原体核酸检测试剂盒于近日取得欧盟 CE IVDR 认证，可在欧盟国家和认可欧盟CE认证的国家进行销售。名称：Logilet Respiratory Pathogen Panel六项呼吸道病原体核酸检测试剂盒，预期用途：用于辅助诊断呼吸道合胞病毒、甲型流感病毒、 乙型流感病毒、严重急性呼吸综合征冠状病毒2 型、腺病毒和肺炎支原体感染。 ...

诺唯赞(688105.SH)公告，公司六项呼吸道病原体核酸检测试剂盒于近日取得欧盟CE IVDR认证，可在 欧盟国家和认可欧盟CE认证的国家进行销售。 ...

智通财经APP讯，诺唯赞(688105.SH)公告，公司六项呼吸道病原体核酸检测试剂盒于近日取得欧盟CE IVDR认证，可在欧盟国家和认可欧盟CE认证的国家进行销售。 ...

诺唯赞公告，公司六项呼吸道病原体核酸检测试剂盒近日取得欧盟CE IVDR认证，可在欧盟国家和认可 欧盟CE认证的国家进行销售。该产品搭配公司数字微流控Logilet Logicore检测系统，依托微流控芯片 完成待测样本的核酸提取、扩增、检测全流程操作，可精准检测6项呼吸道病原体，实现全自动化基因 检测。 ...

中国经济网北京12月9日讯 中证指数有限公司2025年11月28日发布关于沪深300、中证500、中证1000、中证A500 等指数定期调整结果的公告。根据指数规则，经指数专家委员会审议，中证指数有限公司决定调整沪深300、中证 500、中证1000、中证A50、中证A100、中证A500等指数样本，于2025年12月12日收市后生效。其中沪深300指数更换 11只样本，中证500指数更换50只样本，中证1000指数更换100只样本，中证A50指数更换4只样本，中证A100指数更换 6只样本，中证A500指数更换20只样本。 诺唯赞于2021年11月15日在上交所科创板上市，发行数量为4001.00万股，发行价格为55.00元/股，保荐机构（主 承销商）为华泰联合证券有限责任公司，保荐代表人为王正睿、李皓。目前该股处于破发状态。 诺唯赞首次公开发行股票募集资金总额为22.01亿元，扣除发行费用后，募集资金净额为21.09亿元。诺唯赞最终募 集资金净额比原计划多9.07亿元。诺唯赞于2021年11月9日披露的招股书显示，该公司拟募集资金12.02亿元，分别用于 公司总部及研发新基地项目、营销网络扩建项目、补充流 ...

中国经济网北京12月9日讯中证指数有限公司2025年11月28日发布关于沪深300、中证500、中证1000、中证A500等指数 定期调整结果的公告。根据指数规则，经指数专家委员会审议，中证指数有限公司决定调整沪深300、中证500、中证 1000、中证A50、中证A100、中证A500等指数样本，于2025年12月12日收市后生效。其中沪深300指数更换11只样本， 中证500指数更换50只样本，中证1000指数更换100只样本，中证A50指数更换4只样本，中证A100指数更换6只样本， 中证A500指数更换20只样本。 调整结果显示，诺唯赞(688105.SH)被调出中证1000指数样本。 | | 调出名单 | | 调入名单 | | --- | --- | --- | --- | | 605222 | 起帆电缆 | 603887 | 城地香江 | | 605368 | 蓝天燃气 | 605099 | 共创草坪 | | 605577 | 龙版传媒 | 602118 | 力鼎光电 | | 688018 | 乐鑫科技 | 602198 | 安德利 | | 688019 | 安集科技 | 688032 | 禾迈股 ...

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025年12月5日 （二）股东会召开的地点：南京市栖霞区科创路红枫科技园D2栋1楼报告厅 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 表决情况： ■ ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和网络投票相结合的表决方 式。本次股东会的召集和召开程序、出席会议人员资格和召集人资格、会议表决方式和表决结果均符合 《中华人民共和国公司法》及《公司章程》的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席8人，独立董事蔡江南先生因公请假，未列席本次会议。 2、董事会秘书黄金先生列席本次会 ...